229 related articles for article (PubMed ID: 7494560)
1. Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.
Linz W; Wiemer G; Schaper J; Zimmermann R; Nagasawa K; Gohlke P; Unger T; Schölkens BA
Mol Cell Biochem; 1995 Jun 7-21; 147(1-2):89-97. PubMed ID: 7494560
[TBL] [Abstract][Full Text] [Related]
2. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective actions of bradykinin in myocardial ischemia and left ventricular hypertrophy.
Linz W; Wiemer G; Schölkens BA
Braz J Med Biol Res; 1994 Aug; 27(8):1949-54. PubMed ID: 7749386
[TBL] [Abstract][Full Text] [Related]
4. Role of kinins and nitric oxide in the antihypertrophic effect of ramipril.
Rhaleb NE; Yang XP; Scicli AG; Carretero OA
Hypertension; 1994 Jun; 23(6 Pt 2):865-8. PubMed ID: 7515854
[TBL] [Abstract][Full Text] [Related]
5. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation.
Farhy RD; Carretero OA; Ho KL; Scicli AG
Circ Res; 1993 Jun; 72(6):1202-10. PubMed ID: 7684331
[TBL] [Abstract][Full Text] [Related]
6. Contribution of bradykinin to the cardiovascular effects of ramipril.
Linz W; Wiemer G; Schölkens BA
J Cardiovasc Pharmacol; 1993; 22 Suppl 9():S1-8. PubMed ID: 7514234
[TBL] [Abstract][Full Text] [Related]
7. Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.
Nolly H; Miatello R; Damiani MT; Abate CD
Immunopharmacology; 1997 Jun; 36(2-3):185-91. PubMed ID: 9228545
[TBL] [Abstract][Full Text] [Related]
8. Vascular and cardiac protection by ramipril in spontaneously hypertensive rats: prevention versus regression study.
Gohlke P; Linz W; Schölkens B; Van Even P; Martorana P; Unger T
Br J Clin Pract Suppl; 1996 Jul; 84():1-10. PubMed ID: 8994995
[TBL] [Abstract][Full Text] [Related]
9. Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy.
Zhu YC; Zhu YZ; Gohlke P; Stauss HM; Unger T
Am J Cardiol; 1997 Aug; 80(3A):110A-117A. PubMed ID: 9293963
[TBL] [Abstract][Full Text] [Related]
10. Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats.
Gohlke P; Kuwer I; Schnell A; Amann K; Mall G; Unger T
Hypertension; 1997 Jan; 29(1 Pt 2):478-82. PubMed ID: 9039145
[TBL] [Abstract][Full Text] [Related]
11. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.
Liu YH; Yang XP; Sharov VG; Sigmon DH; Sabbath HN; Carretero OA
Hypertension; 1996 Jan; 27(1):7-13. PubMed ID: 8591891
[TBL] [Abstract][Full Text] [Related]
12. Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat.
Rumble JR; Komers R; Cooper ME
J Hypertens; 1996 May; 14(5):601-7. PubMed ID: 8762203
[TBL] [Abstract][Full Text] [Related]
13. Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction.
Linz W; Gohlke P; Unger T; Schölkens BA
Arch Mal Coeur Vaiss; 1995 Feb; 88 Spec No 2():31-4. PubMed ID: 7646309
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin.
Gohlke P; Linz W; Schölkens BA; Kuwer I; Bartenbach S; Schnell A; Unger T
Hypertension; 1994 Apr; 23(4):411-8. PubMed ID: 8144208
[TBL] [Abstract][Full Text] [Related]
15. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril.
Linz W; Schölkens BA
Br J Pharmacol; 1992 Apr; 105(4):771-2. PubMed ID: 1324047
[TBL] [Abstract][Full Text] [Related]
16. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats.
Linz W; Schaper J; Wiemer G; Albus U; Schölkens BA
Br J Pharmacol; 1992 Dec; 107(4):970-5. PubMed ID: 1334756
[TBL] [Abstract][Full Text] [Related]
17. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production.
Ogawa T; Linz W; Stevenson M; Bruneau BG; Kuroski de Bold ML; Chen JH; Eid H; Schölkens BA; de Bold AJ
Circulation; 1996 Jun; 93(11):2059-67. PubMed ID: 8640983
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway.
Rouleau JL; Kapuku G; Pelletier S; Gosselin H; Adam A; Gagnon C; Lambert C; Meloche S
Circulation; 2001 Aug; 104(8):939-44. PubMed ID: 11514383
[TBL] [Abstract][Full Text] [Related]
19. [Effect of a non-antihypertensive dose of ramipril on the plasma and tissue renin-angiotensin system in 27 TGR (mRen2) rats].
Grima M; Anjuère J; Ingert C; Coquard C; Steger J; Barthelmebs M; Imbs JL
Arch Mal Coeur Vaiss; 2001 Aug; 94(8):805-12. PubMed ID: 11575208
[TBL] [Abstract][Full Text] [Related]
20. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker.
Wang CH; Leung N; Lapointe N; Szeto L; Uffelman KD; Giacca A; Rouleau JL; Lewis GF
Circulation; 2003 Apr; 107(14):1923-9. PubMed ID: 12668518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
